Pharma Journalist -

CURE Pharmaceutical announced that it has signed a term sheet with Therapix Biosciences to acquire the non-pain assets of Therapix, subject to the completion of the related conditions.…
Read More...

AbbVie announced an update on a Phase 3 study (DBL3001) of ibrutinib (IMBRUVICA) in untreated (treatment-naïve) diffuse large B-cell lymphoma (DLBCL), an aggressive form of non-Hodgkin…
Read More...

Amphastar Pharmaceuticals announced business expansion plans for its subsidiary, Amphastar Nanjing Pharmaceuticals. To date, ANP has provided Active Pharmaceutical Ingredients and…
Read More...

Filament BioSolutions, a development-stage company focused on delivering innovative therapeutics for nutritional deficiencies, announced continued progress in the development of its…
Read More...

Catalent Pharma Solutions and Berkeley Lights announced Catalent Biologics will adopt BLI’s Beacon optofluidic platform to accelerate its cell line development workflow. The Beacon…
Read More...

Selexis SA announced that under the terms of an earlier commercial license agreement, Symphogen A/S has opened two investigational new drug applications (INDs) for clinical programs…
Read More...

SRI International announced a research agreement with Ionis Pharmaceuticals, combining SRI's proprietary FOX Three Molecular Guidance cellular targeting system (MGS) with Ionis'…
Read More...

BioCryst Pharmaceuticals announced that it has terminated the previously announced merger agreement with Idera Pharmaceuticals following the BioCryst stockholders’ failure to approve…
Read More...

ProBioGen AG and Pionyr Immunotherapeutics announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will…
Read More...

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced that its…
Read More...